Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross NC canakinumab prior auth update | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Canakinumab (Ilaris) subcutaneous injection — Medical Necessity and Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for canakinumab (Ilaris) subcutaneous injection administered by a healthcare professional for approved autoinflammatory and inflammatory indications, governing providers and members covered by Blue Cross NC.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyCanakinumab (Ilaris) subcutaneous injection — Medical Necessity and Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeCriteria additions and revisions (July 2026)
    Effective DateJul 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization (HCPCS J0638) with required documentation of diagnostic confirmation and baseline inflammatory markers.
    SourceLink
    POLICY UPDATE CHANGES

    For CAPS: Added required diagnostic confirmation by either genetic testing or presence of elevated inflammatory markers plus at least two CAPS-typical symptoms.

    For TRAPS: Added required diagnostic confirmation by genetic testing; added requirement for chronic or recurrent disease (>6 flares per year) and submission of baseline CRP levels.

    For HIDS/MKD: Combined criteria; added diagnostic confirmation by genetic testing or significantly elevated serum IgD, requirement for at least 3 febrile episodes in 6 months, and baseline CRP submission.

    For FMF: Added required diagnostic confirmation by genetic testing, requirement for active disease (≥1 febrile episode per month), and baseline CRP submission.

    For SJIA and AOSD: Allowed continuation of canakinumab for patients established on an FDA-approved biologic or systemic immunomodulator if they have had positive clinical benefit; added defined trial durations for conventional agents for AOSD to align with SJIA.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8Distinct indications listed
    365 daysApproval duration (most)
    84 daysApproval duration (gout)
    J0638HCPCS code
    1,050Maximum units

    Coverage Criteria for Canakinumab (Ilaris)

    Initial Therapy

    Covered when ALL of the following are met for the requested indication (Initial Criteria for Approval):

    General: Prescriber is a specialist or has consulted with a specialist; medication will not be used in combination with another biologic immunomodulator agent; requested quantity does not exceed maximum units allowed for the duration of approval; site-of-care criteria apply for inpatient or outpatient administrationsee policy

    Medical record documentation required as specified in indication branches

    Indication-specific

    • CAPS branch
    • TRAPS branch
    • HIDS/MKD branch
    • FMF branch
    • SJIA branch
    • AOSD branch
    • Gout branch

    CAPS

    CAPS branch (must meet ALL):

    CAPS: Diagnosis of Cryopyrin-Associated Periodic Syndrome (CAPS) (including FCAS or Muckle-Wells Syndrome); patient is 4 years of age or older; diagnostic confirmation by ONE of: genetic testing demonstrating a mutation in CIAS1 (NLRP3) OR BOTH elevated baseline serum inflammatory markers (CRP and/or SAA) AND at least two CAPS-typical signs or symptoms (e.g., urticaria-like rash, cold/stress-triggered flares, chronic aseptic meningitis, sensorineural hearing loss, musculoskeletal symptoms, skeletal abnormalities)age ≥4 years; ≥2 symptoms; elevated CRP/SAA

    Medical record documentation required for genetic testing or labs and symptom history

    TRAPS

    TRAPS branch (must meet ALL):

    TRAPS: Diagnosis of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); patient is 2 years of age or older; diagnosis confirmed by genetic testing demonstrating a mutation in TNFRSF1A (TNFR1); chronic or recurrent disease defined as greater than 6 flares per year; documented baseline serum C-reactive protein (CRP) levels>6 flares/year

    Medical record documentation required for genetic testing and baseline CRP

    HIDS / MKD

    HIDS / MKD branch (must meet ALL):

    HIDS/MKD: Diagnosis of Hyperimmunoglobulin D (HIDS) / Mevalonate Kinase Deficiency (MKD); patient is 2 years of age or older; diagnostic confirmation by ONE of: genetic testing demonstrating an MVK mutation OR significantly elevated serum IgD; history of at least 3 febrile episodes within a 6-month period; documented baseline serum C-reactive protein (CRP) levels≥3 febrile episodes in 6 months

    Medical record documentation required for genetic testing or IgD level and febrile episode history and baseline CRP

    FMF

    FMF branch (must meet ALL):

    FMF: Diagnosis of Familial Mediterranean Fever (FMF); patient is 2 years of age or older; diagnosis confirmed by genetic testing demonstrating at least one known MEFV exon 10 mutation; active disease defined as at least one febrile episode per month; AND one of: trial of colchicine for at least a 6-month trial with inadequate response OR intolerance/contraindication to colchicine; documented baseline serum C-reactive protein (CRP) levels≥1 febrile episode/month; colchicine trial ≥6 months

    Medical record documentation required for genetic testing, colchicine trial or intolerance, and baseline CRP

    SJIA

    SJIA branch (must meet ALL):

    SJIA: Diagnosis of active systemic juvenile idiopathic arthritis (SJIA); patient is 2 years of age or older; documented active systemic features (e.g., ongoing fever ≥2 weeks, evanescent erythematous rash, generalized lymphadenopathy, ≥1 joint with active arthritis, hepatomegaly, splenomegaly, serositis); AND ONE of: inadequate response to TWO specified drug classes (DMARDs for ≥3 months, systemic corticosteroids for ≥1 month, NSAIDs for ≥1 month) OR intolerance/contraindication to ALL listed classes OR currently established on a biologic or systemic immunomodulator agent FDA-approved for SJIA with documented positive clinical benefitDMARDs 3 months; systemic corticosteroids 1 month; NSAIDs 1 month

    Medical record documentation required for trials, intolerance, or documentation of clinical benefit for established biologic/systemic immunomodulator use

    AOSD

    AOSD branch (must meet ALL):

    AOSD: Diagnosis of active adult-onset Still's disease (AOSD); patient is 18 years of age or older; ONE of: inadequate response to at least one corticosteroid for ≥1 month OR intolerance/contraindication to corticosteroids; AND ONE of: inadequate response to methotrexate for ≥3 months OR intolerance/contraindication to methotrexate OR currently established on a biologic or systemic immunomodulator agent FDA-approved for AOSD with documented positive clinical benefitcorticosteroid trial ≥1 month; methotrexate ≥3 months

    Medical record documentation required for drug trials, intolerance, or documentation of clinical benefit for established biologic/systemic immunomodulator use

    Gout flares

    Gout flares branch (must meet ALL):

    Gout flares: Diagnosis of gout flares; patient is 18 years of age or older; history of ≥3 flares in the past 12 months; trial and inadequate response to, or intolerance/contraindication to, at least one NSAID AND trial and inadequate response to, or intolerance/contraindication to, colchicine; repeated courses of corticosteroids are not appropriate for the patient; documented baseline information as required≥3 flares/12 months

    Duration of approval limited to 84 days for gout flares; medical record documentation required for prior trials and intolerance/contraindications

    Continuation Therapy

    Continuation Therapy (must meet ALL):

    Continuation: Patient was approved through Blue Cross NC initial criteria for approval OR the patient would have met initial criteria at therapy start; patient has had clinical benefit while on canakinumab therapy (e.g., reduction in inflammatory markers such as CRP, ESR, SAA, or improvement in signs and symptoms); for gout re-treatment, at least a 12-week interval since the last dose; medication will not be used in combination with another biologic immunomodulator agent; prescriber is a specialist or has consulted with a specialist; requested quantity does not exceed maximum units allowed for the duration of approval; site-of-care criteria apply for inpatient or outpatient administrationclinical benefit demonstrated; ≥12-week interval for gout re-treatment

    Medical record documentation required for prior approval, demonstration of clinical benefit, and intervals

    The policy prohibits concurrent use of canakinumab with other biologic immunomodulator therapies. Canakinumab may not be used in combination with another biologic immunomodulator agent; prescribers must confirm the medication will be administered as monotherapy when required by the indication-specific criteria and document any existing biologic therapy status (e.g., established on an FDA‑approved biologic with documented benefit for continuation requests).

    Requests that exceed the plan’s predefined maximum quantity or fail to meet indication‑specific or site‑of‑care requirements are considered not medically necessary. The prescriber must ensure the requested quantity does NOT exceed the maximum units allowed for the duration of approval and must follow the Site of Care rules for inpatient or outpatient administration for injection/infusion requests. Requests that do not meet these requirements may be denied.

    Duration limits apply by indication: Gout flares — 84 days (12 weeks); All other indications — 365 days (1 year). Ensure the requested approval period and total units align with these limits to avoid non‑coverage.

    Coding and Dosing Information

    Covered HCPCS CodesHCPCSCovered
    J0638canakinumab, 1 mg (HCPCS)
    Weight-based dosing thresholds
    Weight > 40 kg150 mg subcutaneous (SC) every 8 weeks
    Weight ≥15 kg and ≤40 kg2 mg/kg subcutaneous (SC) every 8 weeks
    Dosing intervalEvery 8 weeks for all weight-based regimens
    Maximum units allowed
    Policy maximum units1,050 units per approval period
    HCPCS unit definitionCanakinumab billed as J0638 (canakinumab, 1 mg) — units correspond to mg billed
    Approval duration tie-in

    Prior Authorization & Documentation Requirements

    Prior Authorization

    Prior authorization required (HCPCS J0638)

    Prior authorization is required for canakinumab (Ilaris) subcutaneous injection billed with HCPCS code J0638; requests must meet the applicable initial or continuation medical necessity criteria and must not exceed the policy maximum units for the approval duration.

    • Covered HCPCS code: J0638 (canakinumab, 1 mg).
    • Requested quantity must not exceed Maximum Units = 1,050 for the duration of approval.
    • Requests must satisfy initial or continuation criteria in the policy.
    Step Therapy

    Required trials of conventional agents

    For specified indications the policy requires documented trials of conventional therapies with minimum durations (unless intolerant or contraindicated) prior to canakinumab approval.

    • FMF: trial of colchicine for at least a 6-month trial or documented intolerance/contraindication to colchicine (medical record documentation required).

    Background

    Canakinumab (Ilaris) is a human monoclonal antibody that targets and neutralizes interleukin‑1 beta (IL‑1β), reducing inflammation driven by IL‑1β–mediated pathways. It is indicated for several autoinflammatory periodic fever syndromes and inflammatory conditions, including cryopyrin‑associated periodic syndromes, TRAPS, HIDS/MKD, familial Mediterranean fever, systemic juvenile idiopathic arthritis, adult‑onset Still’s disease, and for symptomatic treatment of gout flares when standard therapies are contraindicated, not tolerated, or ineffective. The policy aligns FDA‑labeled indications and dosing with medical necessity requirements and specifies documentation and monitoring (e.g., baseline inflammatory markers and genetic confirmation where required) for many indications.

    Clinical Definitions Referenced in Criteria

    Elevated serum inflammatory markers
    Required baseline markersElevated baseline C-reactive protein (CRP) and/or serum amyloid A (SAA) required for certain indications; medical record documentation required
    Use in diagnostic confirmationElevated CRP/SAA may be required in combination with symptoms (e.g., CAPS requires elevated CRP/SAA plus ≥2 typical signs/symptoms if genetic testing not provided)
    DocumentationMedical record documentation of baseline CRP and/or SAA must be submitted with the request
    Chronic or recurrent disease definition (TRAPS)
    Chronic/recurrent TRAPS definitionDefined as greater than 6 flares per year
    Age requirementPatient must be 2 years of age or older for TRAPS

    Revision History and Policy Updates

    2026-07-01criteria_updateLatest

    Multiple July 2026 updates: CAPS now requires diagnostic confirmation by genetic testing or elevated inflammatory markers plus ≥2 CAPS-typical symptoms; TRAPS requires genetic testing confirmation, definition of chronic/recurrent disease (>6 flares/year) and baseline CRP submission; HIDS and MKD criteria combined with requirement for genetic testing or significantly elevated serum IgD, ≥3 febrile episodes in 6 months, and baseline CRP submission; FMF requires genetic testing confirmation, active disease (≥1 febrile episode/month), and baseline CRP submission; SJIA and AOSD criteria aligned to allow continuation for members established on an FDA‑approved biologic/systemic immunomodulator with documented clinical benefit and to align trial durations for conventional agents for AOSD with SJIA.

    2025-11-01criteria_update

    Site of Care medical necessity criteria updated to add additional bypass for patients with history of severe adverse events or conditions increasing risk for severe adverse events to align with Place of Service for Medical Infusions policy.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyCanakinumab (Ilaris) subcutaneous injection — Medical Necessity and Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeCriteria additions and revisions (July 2026)
    Effective DateJul 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization (HCPCS J0638) with required documentation of diagnostic confirmation and baseline inflammatory markers.
    SourceLink
    On This Page
    Coverage Criteria for Canakinumab (Ilaris)Coding and Dosing InformationPrior Authorization & Documentation RequirementsBackgroundClinical Definitions Referenced in CriteriaRevision History and Policy Updates
    Maximum units apply across the duration of approval (84 days for gout flares; 365 days for other indications)
  1. Gout flares: trial and inadequate response or intolerance/contraindication to at least one NSAID AND trial/inadequate response or intolerance/contraindication to colchicine (medical record documentation required).
  2. SJIA: inadequate response to TWO drug classes which may include DMARDs (≥3 months), systemic corticosteroids (≥1 month), or NSAIDs (≥1 month) OR intolerance/contraindication to listed classes OR currently established on an FDA-approved biologic/systemic immunomodulator with documented clinical benefit.
  3. Documentation Required

    Required supporting documentation

    Medical record documentation must be submitted to support diagnostic confirmation, baseline inflammatory markers, prior therapy trials/intolerance, and clinical benefit for continuation requests.

    • Genetic testing results when required (e.g., NLRP3/CIAS1 for CAPS, TNFRSF1A for TRAPS, MVK for HIDS/MKD, MEFV exon 10 for FMF) or alternative diagnostic lab confirmation (e.g., significantly elevated IgD).
    • Baseline serum inflammatory markers (CRP and/or SAA) as specified per indication; baseline CRP documented for TRAPS, HIDS/MKD, FMF.
    • Documentation of trials and failures or intolerance to prior therapies (e.g., colchicine, NSAIDs, methotrexate, DMARDs, corticosteroids) and evidence of clinical benefit for continuation requests.
    Denial Risk

    Denial risk for criteria non‑adherence

    Requests that do not meet the policy's initial or continuation medical necessity criteria, or that exceed maximum units or site-of-care rules, may be denied.

    • Nonconformance with indication-specific criteria (e.g., missing genetic confirmation, inadequate trial durations, insufficient flare history) risks denial.
    • Requests exceeding the maximum allowed units for the approval duration or not meeting site-of-care requirements may be considered not medically necessary and denied.
    Baseline CRP requirementDocumented baseline serum C-reactive protein (CRP) levels required in the medical record
    2025-09-01criteria_update

    Adjusted maximum units to align with FDA labeling; other minor clarifying updates with no change to policy intent.

    2024-03-01criteria_update

    Added new indication for gout flares with corresponding criteria and dosing table updates.

    2021-10-01criteria_update

    Added Site of Care medical necessity criteria (policy notification given 8/2/2021).